當前位置：首頁 SCI期刊 SCIE期刊醫(yī)學中科院4區(qū) JCRQ2 期刊介紹(非官網(wǎng))

American Journal Of Cardiovascular DrugsSCIE

國際簡稱：AM J CARDIOVASC DRUG 參考譯名：美國心血管藥物雜志

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q2

基本信息：: ISSN：1175-3277; E-ISSN：1179-187X; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區(qū)：NEW ZEALAND; 出版商：Springer International Publishing; 出版語言：English; 出版周期：Bimonthly; 出版年份：2001; 研究方向：醫(yī)學-心血管系統(tǒng)

評價信息：: 影響因子：2.8; H-index：46; CiteScore指數(shù)：6.7; SJR指數(shù)：0.79; SNIP指數(shù)：0.784

發(fā)文數(shù)據(jù)：: Gold OA文章占比：29.66%; 研究類文章占比：51.79%; 年發(fā)文量：56; 自引率：0.0333...; 開源占比：0.2011; 出版撤稿占比：0; 出版國人文章占比：0.12; OA被引用占比：0.2597...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介American Journal Of Cardiovascular Drugs期刊介紹

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

期刊簡介American Journal Of Cardiovascular Drugs期刊介紹

《American Journal Of Cardiovascular Drugs》自2001出版以來，是一本醫(yī)學優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學研究結果，并為醫(yī)學各個領域的原創(chuàng)研究提供一個展示平臺，以促進醫(yī)學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€重要領域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學領域的最新進展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間： 12周，或約稿
醫(yī)學
CARDIAC & CARDIOVASCULAR SYSTEMS
SCIE
中科院4區(qū)
非預警

Cite Score數(shù)據(jù)（2024年最新版）American Journal Of Cardiovascular Drugs Cite Score數(shù)據(jù)

CiteScore：6.7
SJR：0.79
SNIP：0.784

學科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Cardiology and Cardiovascular Medicine	Q1	74 / 387	81%
大類：Medicine 小類：Pharmacology (medical)	Q1	63 / 272	77%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)American Journal Of Cardiovascular Drugs 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區(qū)	小類學科	分區(qū)
醫(yī)學	4區(qū)	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統(tǒng) PHARMACOLOGY & PHARMACY 藥學	4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎，運用科學計量學方法對國際、國內(nèi)學術期刊依據(jù)影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機構的廣泛認可。

中科院分區(qū)表 將所有期刊按照一定指標劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學術期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)American Journal Of Cardiovascular Drugs JCR分區(qū)

2023-2024 年最新版

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	79 / 220	64.3%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	158 / 354	55.5%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	84 / 220	62.05%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	163 / 354	54.1%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學術文獻質(zhì)量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
USA89
CHINA MAINLAND40
Italy21
England18
France13
Spain12
Japan11
Greece10
Australia9
Switzerland9

本刊中國學者近年發(fā)表論文

1、Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
Author: Lou, Yake; Hu, Tianyang; Huang, Jing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 47-57. DOI: 10.1007/s40256-022-00550-9
2、Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry
Author: Millesimo, Michele; Elia, Edoardo; Marengo, Giorgio; De Filippo, Ovidio; Raposeiras-Roubin, Sergio; Wanha, Wojciech; Abu-Assi, Emad; Kinnaird, Tim; Ariza-Sole, Albert; Liebetrau, Christoph; Manzano-Fernandez, Sergio; Iannaccone, Mario; Henriques, Jose Paulo Simao; Templin, Christian; Wilton, Stephen B.; Velicki, Lazar; Xanthopoulou, Ioanna; Correia, Luis; Cerrato, Enrico; Rognoni, Andrea; Nunez-Gil, Ivan; Song, Xiantao; Kawaji, Tetsuma; Quadri, Giorgio; Huczek, Zenon; Paz, Rafael Cobas; Juanatey, Jose Ramon Gonzalez; Nie, Shao-Ping; Kawashiri, Masa-Aki; Dominguez-Rodriguez, Alberto; Conrotto, Federico; D'Ascenzo, Fabrizio; De Ferrari, Gaetano Maria

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 77-87. DOI: 10.1007/s40256-022-00554-5
3、Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial
Author: Zhou, Qiang; Wang, Zhiqiang; Wang, Heming; Chen, Zhidong; Li, Xiaoyi; Dai, Xiangrong; Zhang, Yong; Yu, Xiaohui; Zhou, Renpeng; Hu, Wei

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 101-112. DOI: 10.1007/s40256-022-00562-5
4、Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity
Author: Feng, Jie; Wu, Yanqing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 231-246. DOI: 10.1007/s40256-023-00573-w
5、Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
Author: Zheng, Nan; Zhong, Jinyan; Chen, Xi; Su, Jia; Liu, Chengjiang; Jiang, Longfu

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 257-267. DOI: 10.1007/s40256-023-00574-9
6、Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021
Author: Hao, Jun; Li, Chen; Li, Junrong; Wang, Chuangshi; Li, Yang; He, Chen; Liu, Weida; Li, Sidong; Zuo, Ling; Hui, Wen

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 301-310. DOI: 10.1007/s40256-023-00575-8
7、Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease
Author: Li Li, Shuang Wang, Huilian Huang, Yi Cai, Yutao Xi, Ying Bai, Changsheng Ma

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-019-00330-y
8、The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Author: Hongyu Kuang, Qiang Li, Qijian Yi, Tiewei Lu

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-018-00324-2